nodes	percent_of_prediction	percent_of_DWPC	metapath
Dicyclomine—CYP1A1—Dacarbazine—pancreatic cancer	0.254	0.405	CbGbCtD
Dicyclomine—CYP1A1—Tamoxifen—pancreatic cancer	0.202	0.322	CbGbCtD
Dicyclomine—CYP1A1—Erlotinib—pancreatic cancer	0.172	0.274	CbGbCtD
Dicyclomine—Pruritus—Erlotinib—pancreatic cancer	0.000579	0.00224	CcSEcCtD
Dicyclomine—Discomfort—Fluorouracil—pancreatic cancer	0.000576	0.00222	CcSEcCtD
Dicyclomine—Shock—Irinotecan—pancreatic cancer	0.000574	0.00222	CcSEcCtD
Dicyclomine—Nervous system disorder—Irinotecan—pancreatic cancer	0.000573	0.00221	CcSEcCtD
Dicyclomine—Anaphylactic shock—Gemcitabine—pancreatic cancer	0.000569	0.00219	CcSEcCtD
Dicyclomine—Oedema—Gemcitabine—pancreatic cancer	0.000569	0.00219	CcSEcCtD
Dicyclomine—Hypoaesthesia—Docetaxel—pancreatic cancer	0.000565	0.00218	CcSEcCtD
Dicyclomine—Lethargy—Epirubicin—pancreatic cancer	0.000565	0.00218	CcSEcCtD
Dicyclomine—Confusional state—Fluorouracil—pancreatic cancer	0.000564	0.00218	CcSEcCtD
Dicyclomine—Abdominal pain—Sunitinib—pancreatic cancer	0.00056	0.00216	CcSEcCtD
Dicyclomine—Anaphylactic shock—Fluorouracil—pancreatic cancer	0.000559	0.00216	CcSEcCtD
Dicyclomine—Oedema—Fluorouracil—pancreatic cancer	0.000559	0.00216	CcSEcCtD
Dicyclomine—Nervous system disorder—Gemcitabine—pancreatic cancer	0.000558	0.00215	CcSEcCtD
Dicyclomine—Anorexia—Irinotecan—pancreatic cancer	0.000556	0.00215	CcSEcCtD
Dicyclomine—Diplopia—Epirubicin—pancreatic cancer	0.000554	0.00214	CcSEcCtD
Dicyclomine—Nervous system disorder—Fluorouracil—pancreatic cancer	0.000548	0.00212	CcSEcCtD
Dicyclomine—Dizziness—Tamoxifen—pancreatic cancer	0.000547	0.00211	CcSEcCtD
Dicyclomine—Tachycardia—Fluorouracil—pancreatic cancer	0.000546	0.00211	CcSEcCtD
Dicyclomine—Affect lability—Epirubicin—pancreatic cancer	0.000545	0.0021	CcSEcCtD
Dicyclomine—Anorexia—Gemcitabine—pancreatic cancer	0.000542	0.00209	CcSEcCtD
Dicyclomine—Dizziness—Erlotinib—pancreatic cancer	0.000541	0.00209	CcSEcCtD
Dicyclomine—Face oedema—Epirubicin—pancreatic cancer	0.000535	0.00206	CcSEcCtD
Dicyclomine—Anorexia—Fluorouracil—pancreatic cancer	0.000533	0.00206	CcSEcCtD
Dicyclomine—Eye disorder—Docetaxel—pancreatic cancer	0.000531	0.00205	CcSEcCtD
Dicyclomine—Insomnia—Irinotecan—pancreatic cancer	0.000528	0.00204	CcSEcCtD
Dicyclomine—Cardiac disorder—Docetaxel—pancreatic cancer	0.000527	0.00203	CcSEcCtD
Dicyclomine—Vomiting—Tamoxifen—pancreatic cancer	0.000526	0.00203	CcSEcCtD
Dicyclomine—Mood swings—Epirubicin—pancreatic cancer	0.000525	0.00202	CcSEcCtD
Dicyclomine—Paraesthesia—Irinotecan—pancreatic cancer	0.000524	0.00202	CcSEcCtD
Dicyclomine—Lethargy—Doxorubicin—pancreatic cancer	0.000523	0.00202	CcSEcCtD
Dicyclomine—Hypersensitivity—Sunitinib—pancreatic cancer	0.000522	0.00202	CcSEcCtD
Dicyclomine—Rash—Tamoxifen—pancreatic cancer	0.000522	0.00201	CcSEcCtD
Dicyclomine—Dermatitis—Tamoxifen—pancreatic cancer	0.000521	0.00201	CcSEcCtD
Dicyclomine—Vomiting—Erlotinib—pancreatic cancer	0.000521	0.00201	CcSEcCtD
Dicyclomine—Dyspnoea—Irinotecan—pancreatic cancer	0.00052	0.00201	CcSEcCtD
Dicyclomine—Somnolence—Irinotecan—pancreatic cancer	0.000519	0.002	CcSEcCtD
Dicyclomine—Headache—Tamoxifen—pancreatic cancer	0.000518	0.002	CcSEcCtD
Dicyclomine—Rash—Erlotinib—pancreatic cancer	0.000516	0.00199	CcSEcCtD
Dicyclomine—Dermatitis—Erlotinib—pancreatic cancer	0.000516	0.00199	CcSEcCtD
Dicyclomine—Insomnia—Gemcitabine—pancreatic cancer	0.000514	0.00198	CcSEcCtD
Dicyclomine—Dyspepsia—Irinotecan—pancreatic cancer	0.000514	0.00198	CcSEcCtD
Dicyclomine—Immune system disorder—Docetaxel—pancreatic cancer	0.000513	0.00198	CcSEcCtD
Dicyclomine—Headache—Erlotinib—pancreatic cancer	0.000513	0.00198	CcSEcCtD
Dicyclomine—Diplopia—Doxorubicin—pancreatic cancer	0.000512	0.00198	CcSEcCtD
Dicyclomine—Mediastinal disorder—Docetaxel—pancreatic cancer	0.000512	0.00198	CcSEcCtD
Dicyclomine—Paraesthesia—Gemcitabine—pancreatic cancer	0.000511	0.00197	CcSEcCtD
Dicyclomine—Asthenia—Sunitinib—pancreatic cancer	0.000508	0.00196	CcSEcCtD
Dicyclomine—Decreased appetite—Irinotecan—pancreatic cancer	0.000507	0.00196	CcSEcCtD
Dicyclomine—Dyspnoea—Gemcitabine—pancreatic cancer	0.000507	0.00196	CcSEcCtD
Dicyclomine—Insomnia—Fluorouracil—pancreatic cancer	0.000506	0.00195	CcSEcCtD
Dicyclomine—Somnolence—Gemcitabine—pancreatic cancer	0.000506	0.00195	CcSEcCtD
Dicyclomine—Affect lability—Doxorubicin—pancreatic cancer	0.000504	0.00195	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.000504	0.00195	CcSEcCtD
Dicyclomine—Fatigue—Irinotecan—pancreatic cancer	0.000503	0.00194	CcSEcCtD
Dicyclomine—Paraesthesia—Fluorouracil—pancreatic cancer	0.000502	0.00194	CcSEcCtD
Dicyclomine—Pruritus—Sunitinib—pancreatic cancer	0.000501	0.00194	CcSEcCtD
Dicyclomine—Breast disorder—Epirubicin—pancreatic cancer	0.0005	0.00193	CcSEcCtD
Dicyclomine—Pain—Irinotecan—pancreatic cancer	0.000499	0.00193	CcSEcCtD
Dicyclomine—Constipation—Irinotecan—pancreatic cancer	0.000499	0.00193	CcSEcCtD
Dicyclomine—Dyspnoea—Fluorouracil—pancreatic cancer	0.000498	0.00192	CcSEcCtD
Dicyclomine—Mental disorder—Docetaxel—pancreatic cancer	0.000498	0.00192	CcSEcCtD
Dicyclomine—Somnolence—Fluorouracil—pancreatic cancer	0.000497	0.00192	CcSEcCtD
Dicyclomine—Face oedema—Doxorubicin—pancreatic cancer	0.000495	0.00191	CcSEcCtD
Dicyclomine—Erythema—Docetaxel—pancreatic cancer	0.000494	0.00191	CcSEcCtD
Dicyclomine—Decreased appetite—Gemcitabine—pancreatic cancer	0.000494	0.00191	CcSEcCtD
Dicyclomine—Dyspepsia—Fluorouracil—pancreatic cancer	0.000492	0.0019	CcSEcCtD
Dicyclomine—Nausea—Tamoxifen—pancreatic cancer	0.000492	0.0019	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.000491	0.00189	CcSEcCtD
Dicyclomine—Fatigue—Gemcitabine—pancreatic cancer	0.00049	0.00189	CcSEcCtD
Dicyclomine—Muscular weakness—Epirubicin—pancreatic cancer	0.000488	0.00189	CcSEcCtD
Dicyclomine—Pain—Gemcitabine—pancreatic cancer	0.000486	0.00188	CcSEcCtD
Dicyclomine—Constipation—Gemcitabine—pancreatic cancer	0.000486	0.00188	CcSEcCtD
Dicyclomine—Nausea—Erlotinib—pancreatic cancer	0.000486	0.00188	CcSEcCtD
Dicyclomine—Decreased appetite—Fluorouracil—pancreatic cancer	0.000486	0.00188	CcSEcCtD
Dicyclomine—Mood swings—Doxorubicin—pancreatic cancer	0.000485	0.00187	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000483	0.00186	CcSEcCtD
Dicyclomine—Abdominal distension—Epirubicin—pancreatic cancer	0.000482	0.00186	CcSEcCtD
Dicyclomine—Feeling abnormal—Irinotecan—pancreatic cancer	0.000481	0.00186	CcSEcCtD
Dicyclomine—Pain—Fluorouracil—pancreatic cancer	0.000478	0.00185	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.000477	0.00184	CcSEcCtD
Dicyclomine—Dizziness—Sunitinib—pancreatic cancer	0.000469	0.00181	CcSEcCtD
Dicyclomine—Feeling abnormal—Gemcitabine—pancreatic cancer	0.000469	0.00181	CcSEcCtD
Dicyclomine—Breast disorder—Doxorubicin—pancreatic cancer	0.000463	0.00179	CcSEcCtD
Dicyclomine—Abdominal pain—Irinotecan—pancreatic cancer	0.000461	0.00178	CcSEcCtD
Dicyclomine—Feeling abnormal—Fluorouracil—pancreatic cancer	0.000461	0.00178	CcSEcCtD
Dicyclomine—Muscular weakness—Doxorubicin—pancreatic cancer	0.000452	0.00174	CcSEcCtD
Dicyclomine—Vomiting—Sunitinib—pancreatic cancer	0.000451	0.00174	CcSEcCtD
Dicyclomine—Rash—Sunitinib—pancreatic cancer	0.000447	0.00172	CcSEcCtD
Dicyclomine—Dermatitis—Sunitinib—pancreatic cancer	0.000446	0.00172	CcSEcCtD
Dicyclomine—Abdominal distension—Doxorubicin—pancreatic cancer	0.000446	0.00172	CcSEcCtD
Dicyclomine—Urticaria—Fluorouracil—pancreatic cancer	0.000444	0.00171	CcSEcCtD
Dicyclomine—Headache—Sunitinib—pancreatic cancer	0.000444	0.00171	CcSEcCtD
Dicyclomine—Syncope—Docetaxel—pancreatic cancer	0.000443	0.00171	CcSEcCtD
Dicyclomine—Palpitations—Docetaxel—pancreatic cancer	0.000437	0.00169	CcSEcCtD
Dicyclomine—Loss of consciousness—Docetaxel—pancreatic cancer	0.000435	0.00168	CcSEcCtD
Dicyclomine—Hypersensitivity—Irinotecan—pancreatic cancer	0.00043	0.00166	CcSEcCtD
Dicyclomine—Hypertension—Docetaxel—pancreatic cancer	0.000427	0.00165	CcSEcCtD
Dicyclomine—Drowsiness—Epirubicin—pancreatic cancer	0.000427	0.00165	CcSEcCtD
Dicyclomine—Nausea—Sunitinib—pancreatic cancer	0.000421	0.00162	CcSEcCtD
Dicyclomine—Asthenia—Irinotecan—pancreatic cancer	0.000419	0.00162	CcSEcCtD
Dicyclomine—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000412	0.00159	CcSEcCtD
Dicyclomine—Dry mouth—Docetaxel—pancreatic cancer	0.000412	0.00159	CcSEcCtD
Dicyclomine—Asthenia—Gemcitabine—pancreatic cancer	0.000408	0.00157	CcSEcCtD
Dicyclomine—Confusional state—Docetaxel—pancreatic cancer	0.000407	0.00157	CcSEcCtD
Dicyclomine—Oedema—Docetaxel—pancreatic cancer	0.000404	0.00156	CcSEcCtD
Dicyclomine—Anaphylactic shock—Docetaxel—pancreatic cancer	0.000404	0.00156	CcSEcCtD
Dicyclomine—Pruritus—Gemcitabine—pancreatic cancer	0.000402	0.00155	CcSEcCtD
Dicyclomine—Shock—Docetaxel—pancreatic cancer	0.000397	0.00153	CcSEcCtD
Dicyclomine—Nervous system disorder—Docetaxel—pancreatic cancer	0.000396	0.00153	CcSEcCtD
Dicyclomine—Pruritus—Fluorouracil—pancreatic cancer	0.000396	0.00153	CcSEcCtD
Dicyclomine—Drowsiness—Doxorubicin—pancreatic cancer	0.000395	0.00152	CcSEcCtD
Dicyclomine—Tachycardia—Docetaxel—pancreatic cancer	0.000394	0.00152	CcSEcCtD
Dicyclomine—Dizziness—Irinotecan—pancreatic cancer	0.000386	0.00149	CcSEcCtD
Dicyclomine—Anorexia—Docetaxel—pancreatic cancer	0.000385	0.00148	CcSEcCtD
Dicyclomine—Hypoaesthesia—Epirubicin—pancreatic cancer	0.000381	0.00147	CcSEcCtD
Dicyclomine—Vomiting—Irinotecan—pancreatic cancer	0.000371	0.00143	CcSEcCtD
Dicyclomine—Dizziness—Fluorouracil—pancreatic cancer	0.00037	0.00143	CcSEcCtD
Dicyclomine—Rash—Irinotecan—pancreatic cancer	0.000368	0.00142	CcSEcCtD
Dicyclomine—Dermatitis—Irinotecan—pancreatic cancer	0.000368	0.00142	CcSEcCtD
Dicyclomine—Headache—Irinotecan—pancreatic cancer	0.000366	0.00141	CcSEcCtD
Dicyclomine—Insomnia—Docetaxel—pancreatic cancer	0.000365	0.00141	CcSEcCtD
Dicyclomine—Paraesthesia—Docetaxel—pancreatic cancer	0.000362	0.0014	CcSEcCtD
Dicyclomine—Vomiting—Gemcitabine—pancreatic cancer	0.000362	0.0014	CcSEcCtD
Dicyclomine—Dyspnoea—Docetaxel—pancreatic cancer	0.00036	0.00139	CcSEcCtD
Dicyclomine—Somnolence—Docetaxel—pancreatic cancer	0.000359	0.00138	CcSEcCtD
Dicyclomine—Rash—Gemcitabine—pancreatic cancer	0.000359	0.00138	CcSEcCtD
Dicyclomine—Dermatitis—Gemcitabine—pancreatic cancer	0.000358	0.00138	CcSEcCtD
Dicyclomine—Eye disorder—Epirubicin—pancreatic cancer	0.000358	0.00138	CcSEcCtD
Dicyclomine—Headache—Gemcitabine—pancreatic cancer	0.000356	0.00137	CcSEcCtD
Dicyclomine—Cardiac disorder—Epirubicin—pancreatic cancer	0.000356	0.00137	CcSEcCtD
Dicyclomine—Vomiting—Fluorouracil—pancreatic cancer	0.000355	0.00137	CcSEcCtD
Dicyclomine—Dyspepsia—Docetaxel—pancreatic cancer	0.000355	0.00137	CcSEcCtD
Dicyclomine—Hypoaesthesia—Doxorubicin—pancreatic cancer	0.000353	0.00136	CcSEcCtD
Dicyclomine—Rash—Fluorouracil—pancreatic cancer	0.000353	0.00136	CcSEcCtD
Dicyclomine—Dermatitis—Fluorouracil—pancreatic cancer	0.000352	0.00136	CcSEcCtD
Dicyclomine—Decreased appetite—Docetaxel—pancreatic cancer	0.000351	0.00135	CcSEcCtD
Dicyclomine—Headache—Fluorouracil—pancreatic cancer	0.00035	0.00135	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000348	0.00134	CcSEcCtD
Dicyclomine—Fatigue—Docetaxel—pancreatic cancer	0.000348	0.00134	CcSEcCtD
Dicyclomine—Nausea—Irinotecan—pancreatic cancer	0.000347	0.00134	CcSEcCtD
Dicyclomine—Immune system disorder—Epirubicin—pancreatic cancer	0.000346	0.00134	CcSEcCtD
Dicyclomine—Mediastinal disorder—Epirubicin—pancreatic cancer	0.000345	0.00133	CcSEcCtD
Dicyclomine—Pain—Docetaxel—pancreatic cancer	0.000345	0.00133	CcSEcCtD
Dicyclomine—Constipation—Docetaxel—pancreatic cancer	0.000345	0.00133	CcSEcCtD
Dicyclomine—Nausea—Gemcitabine—pancreatic cancer	0.000338	0.0013	CcSEcCtD
Dicyclomine—Mental disorder—Epirubicin—pancreatic cancer	0.000336	0.0013	CcSEcCtD
Dicyclomine—Erythema—Epirubicin—pancreatic cancer	0.000334	0.00129	CcSEcCtD
Dicyclomine—Feeling abnormal—Docetaxel—pancreatic cancer	0.000333	0.00128	CcSEcCtD
Dicyclomine—Nausea—Fluorouracil—pancreatic cancer	0.000332	0.00128	CcSEcCtD
Dicyclomine—Eye disorder—Doxorubicin—pancreatic cancer	0.000331	0.00128	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.00033	0.00127	CcSEcCtD
Dicyclomine—Cardiac disorder—Doxorubicin—pancreatic cancer	0.000329	0.00127	CcSEcCtD
Dicyclomine—Tension—Epirubicin—pancreatic cancer	0.000327	0.00126	CcSEcCtD
Dicyclomine—Nervousness—Epirubicin—pancreatic cancer	0.000324	0.00125	CcSEcCtD
Dicyclomine—Immune system disorder—Doxorubicin—pancreatic cancer	0.00032	0.00124	CcSEcCtD
Dicyclomine—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.000319	0.00123	CcSEcCtD
Dicyclomine—Abdominal pain—Docetaxel—pancreatic cancer	0.000319	0.00123	CcSEcCtD
Dicyclomine—Vision blurred—Epirubicin—pancreatic cancer	0.000314	0.00121	CcSEcCtD
Dicyclomine—Mental disorder—Doxorubicin—pancreatic cancer	0.000311	0.0012	CcSEcCtD
Dicyclomine—Ill-defined disorder—Epirubicin—pancreatic cancer	0.000309	0.00119	CcSEcCtD
Dicyclomine—Erythema—Doxorubicin—pancreatic cancer	0.000309	0.00119	CcSEcCtD
Dicyclomine—Agitation—Epirubicin—pancreatic cancer	0.000306	0.00118	CcSEcCtD
Dicyclomine—Tension—Doxorubicin—pancreatic cancer	0.000303	0.00117	CcSEcCtD
Dicyclomine—Malaise—Epirubicin—pancreatic cancer	0.000301	0.00116	CcSEcCtD
Dicyclomine—Nervousness—Doxorubicin—pancreatic cancer	0.0003	0.00116	CcSEcCtD
Dicyclomine—Syncope—Epirubicin—pancreatic cancer	0.000299	0.00115	CcSEcCtD
Dicyclomine—Hypersensitivity—Docetaxel—pancreatic cancer	0.000297	0.00115	CcSEcCtD
Dicyclomine—Palpitations—Epirubicin—pancreatic cancer	0.000295	0.00114	CcSEcCtD
Dicyclomine—Loss of consciousness—Epirubicin—pancreatic cancer	0.000293	0.00113	CcSEcCtD
Dicyclomine—Vision blurred—Doxorubicin—pancreatic cancer	0.000291	0.00112	CcSEcCtD
Dicyclomine—Asthenia—Docetaxel—pancreatic cancer	0.00029	0.00112	CcSEcCtD
Dicyclomine—Hypertension—Epirubicin—pancreatic cancer	0.000288	0.00111	CcSEcCtD
Dicyclomine—Ill-defined disorder—Doxorubicin—pancreatic cancer	0.000286	0.0011	CcSEcCtD
Dicyclomine—Pruritus—Docetaxel—pancreatic cancer	0.000286	0.0011	CcSEcCtD
Dicyclomine—Agitation—Doxorubicin—pancreatic cancer	0.000284	0.00109	CcSEcCtD
Dicyclomine—Discomfort—Epirubicin—pancreatic cancer	0.000281	0.00108	CcSEcCtD
Dicyclomine—Malaise—Doxorubicin—pancreatic cancer	0.000278	0.00107	CcSEcCtD
Dicyclomine—Dry mouth—Epirubicin—pancreatic cancer	0.000278	0.00107	CcSEcCtD
Dicyclomine—Syncope—Doxorubicin—pancreatic cancer	0.000277	0.00107	CcSEcCtD
Dicyclomine—Confusional state—Epirubicin—pancreatic cancer	0.000274	0.00106	CcSEcCtD
Dicyclomine—Palpitations—Doxorubicin—pancreatic cancer	0.000273	0.00105	CcSEcCtD
Dicyclomine—Oedema—Epirubicin—pancreatic cancer	0.000272	0.00105	CcSEcCtD
Dicyclomine—Anaphylactic shock—Epirubicin—pancreatic cancer	0.000272	0.00105	CcSEcCtD
Dicyclomine—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000271	0.00105	CcSEcCtD
Dicyclomine—Shock—Epirubicin—pancreatic cancer	0.000268	0.00103	CcSEcCtD
Dicyclomine—Nervous system disorder—Epirubicin—pancreatic cancer	0.000267	0.00103	CcSEcCtD
Dicyclomine—Dizziness—Docetaxel—pancreatic cancer	0.000267	0.00103	CcSEcCtD
Dicyclomine—Hypertension—Doxorubicin—pancreatic cancer	0.000266	0.00103	CcSEcCtD
Dicyclomine—Tachycardia—Epirubicin—pancreatic cancer	0.000266	0.00103	CcSEcCtD
Dicyclomine—Discomfort—Doxorubicin—pancreatic cancer	0.00026	0.001	CcSEcCtD
Dicyclomine—Anorexia—Epirubicin—pancreatic cancer	0.000259	0.001	CcSEcCtD
Dicyclomine—Dry mouth—Doxorubicin—pancreatic cancer	0.000257	0.000992	CcSEcCtD
Dicyclomine—Vomiting—Docetaxel—pancreatic cancer	0.000257	0.00099	CcSEcCtD
Dicyclomine—Rash—Docetaxel—pancreatic cancer	0.000254	0.000982	CcSEcCtD
Dicyclomine—Dermatitis—Docetaxel—pancreatic cancer	0.000254	0.000981	CcSEcCtD
Dicyclomine—Confusional state—Doxorubicin—pancreatic cancer	0.000254	0.00098	CcSEcCtD
Dicyclomine—Headache—Docetaxel—pancreatic cancer	0.000253	0.000976	CcSEcCtD
Dicyclomine—Anaphylactic shock—Doxorubicin—pancreatic cancer	0.000252	0.000972	CcSEcCtD
Dicyclomine—Oedema—Doxorubicin—pancreatic cancer	0.000252	0.000972	CcSEcCtD
Dicyclomine—Shock—Doxorubicin—pancreatic cancer	0.000248	0.000956	CcSEcCtD
Dicyclomine—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000247	0.000953	CcSEcCtD
Dicyclomine—Insomnia—Epirubicin—pancreatic cancer	0.000246	0.00095	CcSEcCtD
Dicyclomine—Tachycardia—Doxorubicin—pancreatic cancer	0.000246	0.000949	CcSEcCtD
Dicyclomine—Paraesthesia—Epirubicin—pancreatic cancer	0.000244	0.000943	CcSEcCtD
Dicyclomine—Dyspnoea—Epirubicin—pancreatic cancer	0.000243	0.000937	CcSEcCtD
Dicyclomine—Somnolence—Epirubicin—pancreatic cancer	0.000242	0.000934	CcSEcCtD
Dicyclomine—Anorexia—Doxorubicin—pancreatic cancer	0.00024	0.000926	CcSEcCtD
Dicyclomine—Nausea—Docetaxel—pancreatic cancer	0.00024	0.000925	CcSEcCtD
Dicyclomine—Dyspepsia—Epirubicin—pancreatic cancer	0.00024	0.000925	CcSEcCtD
Dicyclomine—Decreased appetite—Epirubicin—pancreatic cancer	0.000237	0.000913	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000235	0.000907	CcSEcCtD
Dicyclomine—Fatigue—Epirubicin—pancreatic cancer	0.000235	0.000906	CcSEcCtD
Dicyclomine—Pain—Epirubicin—pancreatic cancer	0.000233	0.000898	CcSEcCtD
Dicyclomine—Constipation—Epirubicin—pancreatic cancer	0.000233	0.000898	CcSEcCtD
Dicyclomine—Insomnia—Doxorubicin—pancreatic cancer	0.000228	0.000879	CcSEcCtD
Dicyclomine—Paraesthesia—Doxorubicin—pancreatic cancer	0.000226	0.000873	CcSEcCtD
Dicyclomine—Dyspnoea—Doxorubicin—pancreatic cancer	0.000225	0.000867	CcSEcCtD
Dicyclomine—Feeling abnormal—Epirubicin—pancreatic cancer	0.000224	0.000866	CcSEcCtD
Dicyclomine—Somnolence—Doxorubicin—pancreatic cancer	0.000224	0.000864	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000223	0.000859	CcSEcCtD
Dicyclomine—Dyspepsia—Doxorubicin—pancreatic cancer	0.000222	0.000856	CcSEcCtD
Dicyclomine—Decreased appetite—Doxorubicin—pancreatic cancer	0.000219	0.000845	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000217	0.000839	CcSEcCtD
Dicyclomine—Fatigue—Doxorubicin—pancreatic cancer	0.000217	0.000838	CcSEcCtD
Dicyclomine—Urticaria—Epirubicin—pancreatic cancer	0.000216	0.000835	CcSEcCtD
Dicyclomine—Constipation—Doxorubicin—pancreatic cancer	0.000215	0.000831	CcSEcCtD
Dicyclomine—Pain—Doxorubicin—pancreatic cancer	0.000215	0.000831	CcSEcCtD
Dicyclomine—Abdominal pain—Epirubicin—pancreatic cancer	0.000215	0.00083	CcSEcCtD
Dicyclomine—Feeling abnormal—Doxorubicin—pancreatic cancer	0.000208	0.000801	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000206	0.000795	CcSEcCtD
Dicyclomine—Hypersensitivity—Epirubicin—pancreatic cancer	0.000201	0.000774	CcSEcCtD
Dicyclomine—Urticaria—Doxorubicin—pancreatic cancer	0.0002	0.000772	CcSEcCtD
Dicyclomine—Abdominal pain—Doxorubicin—pancreatic cancer	0.000199	0.000768	CcSEcCtD
Dicyclomine—Asthenia—Epirubicin—pancreatic cancer	0.000195	0.000754	CcSEcCtD
Dicyclomine—Pruritus—Epirubicin—pancreatic cancer	0.000193	0.000743	CcSEcCtD
Dicyclomine—Hypersensitivity—Doxorubicin—pancreatic cancer	0.000186	0.000716	CcSEcCtD
Dicyclomine—Asthenia—Doxorubicin—pancreatic cancer	0.000181	0.000697	CcSEcCtD
Dicyclomine—Dizziness—Epirubicin—pancreatic cancer	0.00018	0.000695	CcSEcCtD
Dicyclomine—Pruritus—Doxorubicin—pancreatic cancer	0.000178	0.000688	CcSEcCtD
Dicyclomine—Vomiting—Epirubicin—pancreatic cancer	0.000173	0.000668	CcSEcCtD
Dicyclomine—Rash—Epirubicin—pancreatic cancer	0.000172	0.000662	CcSEcCtD
Dicyclomine—Dermatitis—Epirubicin—pancreatic cancer	0.000171	0.000662	CcSEcCtD
Dicyclomine—Headache—Epirubicin—pancreatic cancer	0.000171	0.000658	CcSEcCtD
Dicyclomine—Dizziness—Doxorubicin—pancreatic cancer	0.000167	0.000643	CcSEcCtD
Dicyclomine—Nausea—Epirubicin—pancreatic cancer	0.000162	0.000624	CcSEcCtD
Dicyclomine—Vomiting—Doxorubicin—pancreatic cancer	0.00016	0.000618	CcSEcCtD
Dicyclomine—Rash—Doxorubicin—pancreatic cancer	0.000159	0.000613	CcSEcCtD
Dicyclomine—Dermatitis—Doxorubicin—pancreatic cancer	0.000159	0.000612	CcSEcCtD
Dicyclomine—Headache—Doxorubicin—pancreatic cancer	0.000158	0.000609	CcSEcCtD
Dicyclomine—Nausea—Doxorubicin—pancreatic cancer	0.00015	0.000577	CcSEcCtD
Dicyclomine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—pancreatic cancer	6.33e-05	0.000557	CbGpPWpGaD
Dicyclomine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—pancreatic cancer	6.31e-05	0.000555	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—GAST—pancreatic cancer	6.31e-05	0.000555	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—AGTR1—pancreatic cancer	6.31e-05	0.000555	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—AGTR1—pancreatic cancer	6.29e-05	0.000553	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—SLC2A2—pancreatic cancer	6.27e-05	0.000552	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—AGTR1—pancreatic cancer	6.22e-05	0.000548	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—SCT—pancreatic cancer	6.06e-05	0.000533	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—HEY1—pancreatic cancer	6.06e-05	0.000533	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—SCT—pancreatic cancer	6.04e-05	0.000531	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—HEY1—pancreatic cancer	6.04e-05	0.000531	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—SCT—pancreatic cancer	5.98e-05	0.000526	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—HEY1—pancreatic cancer	5.98e-05	0.000526	CbGpPWpGaD
Dicyclomine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—pancreatic cancer	5.86e-05	0.000516	CbGpPWpGaD
Dicyclomine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—pancreatic cancer	5.84e-05	0.000514	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CCK—pancreatic cancer	5.78e-05	0.000509	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CCK—pancreatic cancer	5.76e-05	0.000507	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CCK—pancreatic cancer	5.71e-05	0.000502	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—GLP1R—pancreatic cancer	5.63e-05	0.000496	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CNR2—pancreatic cancer	5.63e-05	0.000496	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR ligand binding—CXCL8—pancreatic cancer	5.63e-05	0.000495	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CNR2—pancreatic cancer	5.62e-05	0.000494	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—GLP1R—pancreatic cancer	5.62e-05	0.000494	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR ligand binding—CXCL8—pancreatic cancer	5.61e-05	0.000494	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CNR2—pancreatic cancer	5.56e-05	0.000489	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—GLP1R—pancreatic cancer	5.56e-05	0.000489	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR ligand binding—CXCL8—pancreatic cancer	5.56e-05	0.000489	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CCKAR—pancreatic cancer	5.54e-05	0.000488	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CCKAR—pancreatic cancer	5.52e-05	0.000486	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CCKAR—pancreatic cancer	5.47e-05	0.000481	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	5.46e-05	0.000481	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—JAG2—pancreatic cancer	5.37e-05	0.000473	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—JAG2—pancreatic cancer	5.36e-05	0.000471	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—GLP1R—pancreatic cancer	5.33e-05	0.000469	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—JAG2—pancreatic cancer	5.3e-05	0.000467	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—MEN1—pancreatic cancer	5.3e-05	0.000466	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—MEN1—pancreatic cancer	5.28e-05	0.000465	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—DPYD—pancreatic cancer	5.25e-05	0.000462	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—MEN1—pancreatic cancer	5.23e-05	0.00046	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—SHH—pancreatic cancer	5.05e-05	0.000445	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—SHH—pancreatic cancer	5.04e-05	0.000443	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—NOTCH4—pancreatic cancer	5.02e-05	0.000442	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—NOTCH4—pancreatic cancer	5e-05	0.00044	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—IAPP—pancreatic cancer	4.99e-05	0.000439	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—SHH—pancreatic cancer	4.99e-05	0.000439	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—SLC2A2—pancreatic cancer	4.98e-05	0.000438	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—IAPP—pancreatic cancer	4.97e-05	0.000438	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—NOTCH4—pancreatic cancer	4.96e-05	0.000436	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	4.93e-05	0.000434	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—IAPP—pancreatic cancer	4.93e-05	0.000433	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—CD44—pancreatic cancer	4.85e-05	0.000427	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PTHLH—pancreatic cancer	4.79e-05	0.000421	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PTCH1—pancreatic cancer	4.79e-05	0.000421	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PTHLH—pancreatic cancer	4.77e-05	0.00042	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PTCH1—pancreatic cancer	4.77e-05	0.00042	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	4.76e-05	0.000419	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PTHLH—pancreatic cancer	4.73e-05	0.000416	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PTCH1—pancreatic cancer	4.73e-05	0.000416	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—GCG—pancreatic cancer	4.65e-05	0.00041	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—SST—pancreatic cancer	4.38e-05	0.000385	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—STK11—pancreatic cancer	4.38e-05	0.000385	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—SST—pancreatic cancer	4.37e-05	0.000384	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	4.33e-05	0.000381	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—SST—pancreatic cancer	4.32e-05	0.00038	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—PIK3CG—pancreatic cancer	4.32e-05	0.00038	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—PIK3CG—pancreatic cancer	4.31e-05	0.000379	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—JAG1—pancreatic cancer	4.29e-05	0.000377	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—JAG1—pancreatic cancer	4.27e-05	0.000376	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—NOTCH3—pancreatic cancer	4.27e-05	0.000376	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—PIK3CG—pancreatic cancer	4.26e-05	0.000375	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—NOTCH3—pancreatic cancer	4.26e-05	0.000374	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—JAG1—pancreatic cancer	4.23e-05	0.000372	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—NOTCH3—pancreatic cancer	4.21e-05	0.000371	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CNR1—pancreatic cancer	4.04e-05	0.000356	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CNR1—pancreatic cancer	4.03e-05	0.000355	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CNR1—pancreatic cancer	3.99e-05	0.000351	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—PIK3CG—pancreatic cancer	3.92e-05	0.000345	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—PIK3CG—pancreatic cancer	3.91e-05	0.000344	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—GCG—pancreatic cancer	3.9e-05	0.000344	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—GCG—pancreatic cancer	3.89e-05	0.000342	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—PIK3CG—pancreatic cancer	3.87e-05	0.000341	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—CD44—pancreatic cancer	3.86e-05	0.000339	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—GCG—pancreatic cancer	3.85e-05	0.000339	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—PIK3CD—pancreatic cancer	3.8e-05	0.000334	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—PIK3CD—pancreatic cancer	3.79e-05	0.000333	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	3.78e-05	0.000332	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—TYMS—pancreatic cancer	3.76e-05	0.000331	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—PIK3CD—pancreatic cancer	3.75e-05	0.00033	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	3.74e-05	0.000329	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—AGTR1—pancreatic cancer	3.72e-05	0.000328	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—AGTR1—pancreatic cancer	3.71e-05	0.000327	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—GCG—pancreatic cancer	3.7e-05	0.000325	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—AGTR1—pancreatic cancer	3.68e-05	0.000324	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—STK11—pancreatic cancer	3.67e-05	0.000323	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—STK11—pancreatic cancer	3.66e-05	0.000322	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—STK11—pancreatic cancer	3.62e-05	0.000319	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—STK11—pancreatic cancer	3.48e-05	0.000306	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—PIK3CD—pancreatic cancer	3.45e-05	0.000303	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—PIK3CD—pancreatic cancer	3.44e-05	0.000303	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—PIK3CD—pancreatic cancer	3.4e-05	0.0003	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—PIK3CB—pancreatic cancer	3.31e-05	0.000291	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—PIK3CB—pancreatic cancer	3.3e-05	0.00029	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—PIK3CB—pancreatic cancer	3.27e-05	0.000288	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	3.26e-05	0.000287	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—SMAD4—pancreatic cancer	3.22e-05	0.000283	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—SMAD4—pancreatic cancer	3.21e-05	0.000282	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—CXCL8—pancreatic cancer	3.18e-05	0.00028	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—SMAD4—pancreatic cancer	3.17e-05	0.000279	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—CXCL8—pancreatic cancer	3.17e-05	0.000279	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—CXCL8—pancreatic cancer	3.14e-05	0.000276	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—HES1—pancreatic cancer	3.14e-05	0.000276	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—HES1—pancreatic cancer	3.13e-05	0.000275	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—HES1—pancreatic cancer	3.1e-05	0.000273	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—APOE—pancreatic cancer	3.06e-05	0.000269	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—PIK3CB—pancreatic cancer	3.01e-05	0.000265	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—PIK3CB—pancreatic cancer	3e-05	0.000264	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—TYMS—pancreatic cancer	2.99e-05	0.000263	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—PIK3CB—pancreatic cancer	2.97e-05	0.000261	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—CXCL8—pancreatic cancer	2.89e-05	0.000254	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—CXCL8—pancreatic cancer	2.88e-05	0.000253	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—CXCL8—pancreatic cancer	2.85e-05	0.000251	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PIK3CG—pancreatic cancer	2.76e-05	0.000243	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—TERT—pancreatic cancer	2.75e-05	0.000242	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—TERT—pancreatic cancer	2.74e-05	0.000241	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—TERT—pancreatic cancer	2.72e-05	0.000239	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PPARG—pancreatic cancer	2.67e-05	0.000235	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—HIF1A—pancreatic cancer	2.63e-05	0.000231	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—TSC2—pancreatic cancer	2.62e-05	0.000231	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—HIF1A—pancreatic cancer	2.62e-05	0.000231	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—TSC2—pancreatic cancer	2.62e-05	0.00023	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—HIF1A—pancreatic cancer	2.6e-05	0.000228	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—TSC2—pancreatic cancer	2.59e-05	0.000228	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—APOE—pancreatic cancer	2.57e-05	0.000226	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—APOE—pancreatic cancer	2.56e-05	0.000225	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—APOE—pancreatic cancer	2.54e-05	0.000223	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—KDR—pancreatic cancer	2.52e-05	0.000221	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—KDR—pancreatic cancer	2.51e-05	0.000221	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—KDR—pancreatic cancer	2.48e-05	0.000219	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—APOE—pancreatic cancer	2.43e-05	0.000214	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PIK3CD—pancreatic cancer	2.43e-05	0.000214	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—NFKBIA—pancreatic cancer	2.39e-05	0.000211	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—NFKBIA—pancreatic cancer	2.39e-05	0.00021	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—NOTCH1—pancreatic cancer	2.37e-05	0.000209	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—NOTCH1—pancreatic cancer	2.36e-05	0.000208	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—NFKBIA—pancreatic cancer	2.36e-05	0.000208	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—NOTCH1—pancreatic cancer	2.34e-05	0.000206	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PIK3CG—pancreatic cancer	2.32e-05	0.000204	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—NRAS—pancreatic cancer	2.32e-05	0.000204	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PIK3CG—pancreatic cancer	2.31e-05	0.000203	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—NRAS—pancreatic cancer	2.31e-05	0.000203	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	2.3e-05	0.000203	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—EGF—pancreatic cancer	2.29e-05	0.000202	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PIK3CG—pancreatic cancer	2.29e-05	0.000201	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—NRAS—pancreatic cancer	2.29e-05	0.000201	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—EGF—pancreatic cancer	2.28e-05	0.000201	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—EGF—pancreatic cancer	2.26e-05	0.000199	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PIK3CG—pancreatic cancer	2.2e-05	0.000193	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PPARG—pancreatic cancer	2.12e-05	0.000186	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PIK3CB—pancreatic cancer	2.12e-05	0.000186	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—EGFR—pancreatic cancer	2.11e-05	0.000186	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—EGFR—pancreatic cancer	2.1e-05	0.000185	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PTGS2—pancreatic cancer	2.1e-05	0.000185	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—EGFR—pancreatic cancer	2.08e-05	0.000183	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PIK3CD—pancreatic cancer	2.04e-05	0.000179	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PIK3CD—pancreatic cancer	2.03e-05	0.000179	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—PIK3CA—pancreatic cancer	2.02e-05	0.000178	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—PIK3CA—pancreatic cancer	2.01e-05	0.000177	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PIK3CD—pancreatic cancer	2.01e-05	0.000177	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—KRAS—pancreatic cancer	1.99e-05	0.000176	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.99e-05	0.000175	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—KRAS—pancreatic cancer	1.99e-05	0.000175	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—KRAS—pancreatic cancer	1.97e-05	0.000173	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PIK3CD—pancreatic cancer	1.93e-05	0.00017	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—PIK3CA—pancreatic cancer	1.83e-05	0.000161	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PTEN—pancreatic cancer	1.83e-05	0.000161	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—PIK3CA—pancreatic cancer	1.83e-05	0.000161	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—PIK3CA—pancreatic cancer	1.81e-05	0.000159	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PIK3CB—pancreatic cancer	1.78e-05	0.000156	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PIK3CB—pancreatic cancer	1.77e-05	0.000156	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PIK3CB—pancreatic cancer	1.75e-05	0.000154	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CXCL8—pancreatic cancer	1.71e-05	0.00015	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CXCL8—pancreatic cancer	1.7e-05	0.00015	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—HRAS—pancreatic cancer	1.7e-05	0.000149	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—HRAS—pancreatic cancer	1.69e-05	0.000149	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CXCL8—pancreatic cancer	1.68e-05	0.000148	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PIK3CB—pancreatic cancer	1.68e-05	0.000148	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—HRAS—pancreatic cancer	1.67e-05	0.000147	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PTGS2—pancreatic cancer	1.67e-05	0.000147	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—AKT1—pancreatic cancer	1.65e-05	0.000145	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—AKT1—pancreatic cancer	1.64e-05	0.000145	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CASP3—pancreatic cancer	1.63e-05	0.000144	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CASP3—pancreatic cancer	1.63e-05	0.000143	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—AKT1—pancreatic cancer	1.63e-05	0.000143	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CASP3—pancreatic cancer	1.61e-05	0.000142	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CCND1—pancreatic cancer	1.59e-05	0.00014	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CCND1—pancreatic cancer	1.58e-05	0.000139	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CTNNB1—pancreatic cancer	1.57e-05	0.000139	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CCND1—pancreatic cancer	1.57e-05	0.000138	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CTNNB1—pancreatic cancer	1.57e-05	0.000138	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CTNNB1—pancreatic cancer	1.55e-05	0.000137	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—MMP9—pancreatic cancer	1.54e-05	0.000136	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—MMP9—pancreatic cancer	1.54e-05	0.000135	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PTEN—pancreatic cancer	1.53e-05	0.000135	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PTEN—pancreatic cancer	1.53e-05	0.000135	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—MMP9—pancreatic cancer	1.52e-05	0.000134	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PTEN—pancreatic cancer	1.51e-05	0.000133	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—AKT1—pancreatic cancer	1.5e-05	0.000132	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—AKT1—pancreatic cancer	1.49e-05	0.000131	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—AKT1—pancreatic cancer	1.48e-05	0.00013	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PTEN—pancreatic cancer	1.45e-05	0.000128	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—SRC—pancreatic cancer	1.42e-05	0.000125	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—SRC—pancreatic cancer	1.42e-05	0.000125	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—SRC—pancreatic cancer	1.4e-05	0.000124	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—VEGFA—pancreatic cancer	1.39e-05	0.000122	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—VEGFA—pancreatic cancer	1.38e-05	0.000122	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—STAT3—pancreatic cancer	1.37e-05	0.000121	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—NRAS—pancreatic cancer	1.37e-05	0.00012	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—VEGFA—pancreatic cancer	1.37e-05	0.00012	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—STAT3—pancreatic cancer	1.37e-05	0.00012	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—NRAS—pancreatic cancer	1.36e-05	0.00012	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—STAT3—pancreatic cancer	1.35e-05	0.000119	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—NRAS—pancreatic cancer	1.35e-05	0.000119	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PIK3CA—pancreatic cancer	1.29e-05	0.000114	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—MYC—pancreatic cancer	1.28e-05	0.000112	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—TGFB1—pancreatic cancer	1.27e-05	0.000112	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—MYC—pancreatic cancer	1.27e-05	0.000112	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—TGFB1—pancreatic cancer	1.27e-05	0.000112	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—MYC—pancreatic cancer	1.26e-05	0.000111	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—TGFB1—pancreatic cancer	1.26e-05	0.00011	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—EGFR—pancreatic cancer	1.25e-05	0.00011	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—EGFR—pancreatic cancer	1.24e-05	0.000109	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—EGFR—pancreatic cancer	1.23e-05	0.000108	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—KRAS—pancreatic cancer	1.18e-05	0.000104	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—KRAS—pancreatic cancer	1.17e-05	0.000103	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—KRAS—pancreatic cancer	1.16e-05	0.000102	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PIK3CA—pancreatic cancer	1.08e-05	9.53e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PIK3CA—pancreatic cancer	1.08e-05	9.5e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PIK3CA—pancreatic cancer	1.07e-05	9.4e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—AKT1—pancreatic cancer	1.05e-05	9.28e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—TP53—pancreatic cancer	1.05e-05	9.22e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—TP53—pancreatic cancer	1.04e-05	9.19e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—TP53—pancreatic cancer	1.03e-05	9.1e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PIK3CA—pancreatic cancer	1.03e-05	9.02e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—HRAS—pancreatic cancer	1e-05	8.81e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—HRAS—pancreatic cancer	9.98e-06	8.78e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—HRAS—pancreatic cancer	9.89e-06	8.7e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—AKT1—pancreatic cancer	8.84e-06	7.78e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—AKT1—pancreatic cancer	8.82e-06	7.76e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—AKT1—pancreatic cancer	8.73e-06	7.68e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—AKT1—pancreatic cancer	8.38e-06	7.37e-05	CbGpPWpGaD
